Cellmid Limited (ASX:CDY) is making changes to its board of directors to reflect its focus on accelerating the expansion of its consumer health business.
Graeme Kaufman and Martin Rogers have stepped down as non-executive directors of the company with effect from 30th June 2015 while Bruce Gordon will be appointed as a non-executive director from 1st July 2015.
Gordon has over 25 years of audit and finance experience in industries such as retail, healthcare, resources and manufacturing.
He was most recently Partner in Charge of BDO Australia’s National Corporate Finance Team.
Gordon has had a long association with Cellmid through his roles at BDO and has a thorough understanding of the company’s operations, including both the midkine and the consumer health businesses.
He brings considerable international corporate finance experience to his role as non-executive director of Cellmid, in addition to his deep knowledge of the company.
Kaufman joined Cellmid in August 2012 and advanced the business with his deep industry knowledge coupled with his intimate understanding of the midkine asset portfolio.
Rogers increased the company’s profile with investors and assisted in a number of capital raising since he was appointed in September 2012.
Earlier this month, Cellmid secured a $1 million research and development loan funding from Platinum Road that along with existing resources will allow it to accelerate the successful launch campaign of its évolis® hair growth products and proceed with the toxicology component of its preclinical anti-midkine antibody program.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.